Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 17/20 | 0.89 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.89 |
| ▸ | MLNR | O43193 | 1/20 | 0.89 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.89 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.89 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.89 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.89 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.89 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.89 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.89 |
| ▸ | DRD2 | P14416 | 1/20 | 0.89 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.89 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.89 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.89 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.89 |
| ▸ | NPY1R | P25929 | 1/20 | 0.89 |
| ▸ | HTR2A | P28223 | 1/20 | 0.89 |
| ▸ | HTR2C | P28335 | 1/20 | 0.89 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.89 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL668295 | 1.00 | ESR1 (0.89) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL6678781 | 1.00 | ESR1 (0.89) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL282198 | 1.00 | ESR1 (0.89) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL7958525 | 0.95 | ESR1 (0.98) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL7958955 | 0.95 | ESR1 (0.98) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL7958527 | 0.95 | ESR1 (0.98) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL667299 | 0.94 | ESR1 (0.82) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL282395 | 0.94 | ESR1 (0.82) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL6677235 | 0.94 | ESR1 (0.82) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL667298 | 0.94 | ESR1 (0.82) | ESR1ESR2MLNRNR1I2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 370 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0883404-B1 | COMBINATION THERAPY FOR OSTEOPOROSIS | PFIZER (US) | 2008-08-20 | — | — | EP | claimed |
| EP-1932543-A2 | Combination therapy for osteoporosis consisting of an estrogen agonist/antagonist and a growth hormone secretagogue | Pfizer, Inc. (US) | 2008-06-18 | — | — | EP | claimed |
| EP-0989993-B1 | TARTRATE SALT OF A SUBSTITUTED DIPEPTIDE AS GROWTH HORMONE SECRETAGOGUE | PFIZER PROD INC (US) | 2008-03-05 | — | — | EP | claimed |
| US-7255984-B2 | Combination therapy for osteoporosis | PFIZER INC. (US) | 2007-08-14 | — | — | US | claimed |
| EP-1383482-B1 | METHOD FOR MANUFACTURING A LOW DOSE PHARMACEUTICAL COMPOSITION | PFIZER PROD INC (US) | 2007-07-18 | — | — | EP | claimed |
| EP-1001970-B1 | DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES | PFIZER (US) | 2007-03-07 | — | — | EP | claimed |
| US-7176221-B2 | Low dose pharmaceutical composition having uniform drug distribution and potency | PFIZER INC. (US) | 2007-02-13 | — | — | US | claimed |
| EP-1021410-B1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER (US) | 2006-12-27 | — | — | EP | claimed |
| EP-0946501-B1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER (US) | 2006-05-31 | — | — | EP | claimed |
| US-20060093667-A1 | Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency | PFIZER INC | 2006-05-04 | — | — | US | claimed |
| US-6194578-B1 | GROWTH HORMONE SECRETAGOGUES; USEFUL FOR PROPHYLAXIS AND THERAPY OF OSTEOPOROSIS AND/OR FRAILTY, INSULIN RESISTANCE IN MAMMALS, CONGESTIVE HEART FAILURE, OBESITY, ACCELERATING BONE FRACTURE REPAIR REDUCING CACHEXIA AND PROTEIN LOSS | PFIZER INC. | 2001-02-27 | — | — | US | claimed |
| US-6124314-A | A PROSTAGLANDIN AGONISTS FOR TREATING VERTEBRATE BONE DISORDERS | PFIZER INC. (US) | 2000-09-26 | — | — | US | claimed |
| US-6124264-A | GROWTH HORMONE SECRETAGOGUE IN A HUMAN OR OTHER ANIMAL TO TREAT OSTEOPOROSIS, CONGESTIVE HEART FAILURE, AGING, OBESITY; BONE AND WOUND HEALING AGENTS | PFIZER INC. (US) | 2000-09-26 | — | — | US | claimed |
| WO-2000041700-A1 | USE OF ESTROGENS AND DELTA-GONADIEN-21-OL-3,20-DIONES IN THE TREATMENT OR PROPHYLAXIS OF CEREBRAL DEGENERATIVE DISORDERS | NOVO NORDISK A/S (DK) | 2000-07-20 | — | — | WO | claimed |
| WO-2000041701-A1 | USE OF ESTROGENS AND DELTA-GONADIEN-21-OL-3,20-DIONES FOR TREATING INSULIN DEPENDENT AND NON-INSULIN DEPENDENT DIABETES | NOVO NORDISK A/S (DK) | 2000-07-20 | — | — | WO | claimed |
| EP-1002802-A1 | Dipeptide derivatives as growth hormone secretagogues | Pfizer Products Inc. (US) | 2000-05-24 | — | — | EP | claimed |
| EP-0995748-A1 | Growth hormone secretagogues | Pfizer Products Inc. (US) | 2000-04-26 | — | — | EP | claimed |
| US-6034102-A | CARDIOVASCULAR DISORDERS | PFIZER INC (US) | 2000-03-07 | — | — | US | claimed |
| EP-0976404-A2 | A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal | Pfizer Products Inc. (US) | 2000-02-02 | — | — | EP | claimed |
| EP-0911321-A2 | Compounds for the treatment of osteoporosis | PFIZER INC. (US) | 1999-04-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060093667-A1 | Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency | SRI, SIK2, PDE9A | ESR1 4095/4885ESR2 4483/4885MLNR 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.